Phaseline

Targets › SLC23A2

SLC23A2 (Solute carrier family 23 member 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Oncology; next expected readout Mar 2028.

Sodium/ascorbate cotransporter. Mediates electrogenic uptake of vitamin C, with a stoichiometry of 2 Na(+) for each ascorbate. (UniProt, Q9UGH3)

Open in Phaseline: the race on SLC23A2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
UroGen PharmaUGN-102
Mitomycin-hydrogel intravesical solution; mitomycin is a DNA alkylating agent
SLC23A2Phase 3Bladder CancerMar 2028

Conditions

Bladder Cancer (1)

Modalities

small molecule (1)

Companies

UroGen Pharma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.